Trastuzumab emtansine

Drug Profile

Trastuzumab emtansine

Alternative Names: Ado-trastuzumab emtansine; DM1-trastuzumab immunoconjugate; Kadcyla; PRO-132365; R3502; RG 3502; RO 5304020; T-DM1; Trastuzumab-DM1; Trastuzumab-DM1 immunoconjugate; Trastuzumab-MCC-DM1; Trastuzumab-MCC-DM1 antibody-drug conjugate; Trastuzumab–SMCC–DM1 conjugate

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Genentech; ImmunoGen
  • Developer Chugai Pharmaceutical; Genentech; Memorial Sloan-Kettering Cancer Center; Roche
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Macrolides; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Bladder cancer; Lung cancer; Non-small cell lung cancer; Solid tumours; Urogenital cancer
  • Discontinued Gastric cancer

Most Recent Events

  • 29 Dec 2016 NICE to discuss comments from HCP, company and public on the 2015 guidance on the funding of trastuzumab emtansine on the NHS
  • 22 Sep 2016 Phase-II clinical trials in Solid tumours (Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable, Late-stage disease) in Spain (IV) (EudraCT2015-001377-40)
  • 21 Jul 2016 Phase-II clinical trials in Breast cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (IV) (EudraCT2015-004189-27) after July 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top